200
Participants
Start Date
January 2, 2026
Primary Completion Date
August 31, 2029
Study Completion Date
February 28, 2030
Empagliflozin
A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Placebo
A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
VA Palo Alto Health Care System, Palo Alto, CA, Palo Alto
Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
Michael E. DeBakey VA Medical Center, Houston, TX, Houston
VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City
Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond
William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison
VA Office of Research and Development
FED